Talis Biomedical (NASDAQ:TLIS) Shares Down 1.5% – Here’s Why

Talis Biomedical Co. (NASDAQ:TLIS)’s stock price dropped 1.5% during trading on Thursday . The stock traded as low as $1.64 and last traded at $1.70. Approximately 1,506 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 14,400 shares. The stock had previously closed at $1.72.

Talis Biomedical Stock Performance

The stock has a market capitalization of $3.08 million, a PE ratio of -0.05 and a beta of 1.57. The business’s 50-day moving average price is $3.17 and its 200 day moving average price is $6.83.

Talis Biomedical (NASDAQ:TLIS) last posted its earnings results on Monday, August 19th. The company reported ($4.86) EPS for the quarter. Talis Biomedical had a negative return on equity of 79.74% and a negative net margin of 5,784.73%.

Insider Buying and Selling

In related news, major shareholder Braden Michael Leonard purchased 13,167 shares of the business’s stock in a transaction on Monday, August 26th. The stock was acquired at an average price of $3.90 per share, with a total value of $51,351.30. Following the purchase, the insider now directly owns 216,736 shares in the company, valued at approximately $845,270.40. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have purchased 15,033 shares of company stock worth $58,804. Insiders own 46.00% of the company’s stock.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.